The relationship between Helicobacter pylori infection and gastric cancer has been evaluated in epidemiological studies, animal experiments, and clinical studies. In the epidemiological area, many studies using anti-H. pylori antibody have been reported. Five meta-analyses of cohort studies, case-control studies, and nested casecontrol studies have revealed a positive odds ratio between H. pylori seropositivity and gastric cancer [1] [2] [3] [4] ( Table 1 ). In animal studies using the Mongolian gerbil, H. pylori infection increases the incidence ratio of gastric cancer [5] [6] [7] [8] [9] [10] (Table 2) . Also, gastric cancer prevention through H. pylori eradication based on this animal model has already been shown. Many factors are associated with the development of gastric cancer [11] [12] [13] ( Fig. 1 ). Carcinogenesis factors include environment, host genetics, level of acid secretion, duration of H. pylori infection, and virulence of the H. pylori strain.
14 Environmental factors include high salt consumption and tobacco use. However, H. pylori plays an important role in gastric carcinogenesis. H. pylori infection is necessary for gastric cancer carcinogenesis, but not sufficient. Therefore, eradication of H. pylori may inhibit the incidence of gastric cancer. The outcome of H. pylori infection depends on the kind of gastritis. 15 Intestinaltype gastric cancer usually occurs after corpuspredominant gastritis, while diffuse-type gastric cancer arises from pangastritis. Usually gastric cancer does not occur when the type of gastritis is antrum-predominant gastritis.
However, compared with epidemiological studies and animal studies, not enough evidence is available from human intervention studies conducted to determine whether H. pylori eradication reduces the incidence of gastric cancer. The results of two recent large-scale randomized controlled studies in China are absolutely contraversial 16, 17 (Table 3 ). The study of Wong et al. 16 Because most gastric cancers develop from a background of Helicobacter pylori-infected gastric mucosa, H. pylori plays an important role in gastric carcinogenesis. Therefore, eradication of H. pylori may inhibit the incidence of gastric cancers. In experimental studies, H. pylori eradication has proved to act as a prophylaxis against gastric cancer. However, the results of recent randomized controlled studies are absolutely contradictory. In Japan, mucosal gastric cancer is usually resected by endoscopic treatment. As only a small part of the gastric mucosa is resected, secondary gastric cancer after endoscopic resection of the primary gastric cancer often develops at another site in the stomach. A nonrandomized Japanese study involving 132 early gastric cancer patients reported that eradication of H. pylori after endoscopic resection tended to reduce the development of secondary gastric cancer. Also, a retrospective multicenter survey indicated that the incidence rate of secondary gastric cancer in H. pylori-eradicated patients was about one-third that among patients in the noneradication group. We conducted a large-scale multicenter randomized trial to confirm the effect of H. pylori eradication on secondary and residual gastric cancer after endoscopic resection. This study was begun in 2003 and is ongoing at present. Diagnosis of a new carcinoma at another site of the stomach is defined as the primary end point, and recurrence of tumors at the resection site as a secondary end point. A total of 542 subjects have been enrolled in the study. This study will have the statistical power to demonstrate whether H. pylori eradication decreases the incidence and recurrence of gastric cancer.
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H. pylori eradication on the prevention of primary gastric cancer has thus not been confirmed in clinical interventional studies. A nonrandomized Japanese study by Uemura et al. 18 involving 132 early gastric cancer patients reported that eradication of H. pylori after endoscopic resection tended to reduce the development of secondary gastric cancer. Although the relationship between H. pylori infection and gastric cancer is now accepted, the effectiveness of H. pylori eradication for prevention of gastric cancer has not been clarified.
Retrospective study in Japan
It is not unusual for gastric cancers to be detected after successful eradication of H. pylori. However, the frequency of gastric cancer occurring after successful eradication has not been investigated in Japan. Two retrospective multicenter studies were conducted at 41 institutions in Japan to investigate the incidence in Japan of primary and secondary gastric cancer after H. pylori eradication. 19, 20 The first study compared the incidence of primary gastric cancer between two groups that were followed for 5 years; H. pylori was successfully eradicated in the eradication group, but persisted in the noneradication group. The second study compared the secondary gastric cancer between two groups after the primary cancer had been removed by endoscopic treatment. Next, the characteristics of primary and secondary gastric cancer after successful eradication were compared. showed that H. pylori eradication significantly decreased the incidence of gastric cancer. The effect of
In all, 3021 patients participated in the primary gastric cancer study. The follow-up period was significantly shorter in the eradication group. The female-to-male ratio and duodenal ulcer ratio were significantly higher in the eradication group. Gastric cancers developed in 23 patients (1.3%) whose H. pylori had been successfully eradicated, and in 44 patients (3.6%) with persistent H. pylori infection during the 7.7-year follow-up of the primary gastric cancer study. The incidence ratio of primary gastric cancer was significantly lower in the eradication group [odds ratio OR = 0.36; 95% confidence interval (CI) = 0.22-0.62].
A total of 2835 patients participated in the secondary gastric cancer study. Secondary gastric cancers developed in eight patients (2.2%) whose H. pylori had been successfully eradicated and in 129 patients (5.2%) with persistent H. pylori infection. The incidence ratio of secondary gastric cancer was significantly lower in the eradication group (OR = 0.42; 95% CI = 0.20-0.86).
The characteristics of gastric cancer were investigated among three groups: primary gastric cancer without eradication as the control; primary gastric cancer with eradication; and secondary gastric cancer with eradication. There were significant differences in tumor size between the control primary gastric cancer without eradication and the secondary gastric cancer with eradication groups (Fig. 2) . Comparison of the gastric cancer characteristics revealed that the ulcer-negative ratio, the mucosal cancer ratio, and the intestinal-type ratio increased in the order control, primary gastric cancer with eradication, and secondary gastric cancer with eradication. There was no difference among the three groups with respect to morphological type of cancer (Fig. 3) . This retrospective study showed that H. pylori eradication may reduce the development of gastric cancer. There was retrospectively only a little different in the characteristics of gastric cancer between the eradication and noneradication groups.
Prospective study in Japan
In Japan, mucosal gastric cancer is usually resected endoscopically. Conventional endoscopic mucosal resection (EMR) consists of three steps in principle: marking, lifting by submucosal injection, and snaring and cutting. There are different snaring methods, such as the EMRcup, EMR-2 channel, EMR-ligation methods. According to the gastric cancer treatment guidelines of the Japanese Gastric Cancer Association, conventional EMR is indicated for mucosal cancer of the intestinal type measuring less than 2 cm in diameter and without Fig. 3 . Comparison of gastric cancer characteristics among groups revealed that the ulcer-negative ratio, mucosal cancer ratio, and intestinal-type ratio increased in the order control group, primary gastric cancer with eradication group, and secondary gastric cancer with eradication group evidence of an ulcer or an ulcer scar. 21 A recently developed EMR procedure, endoscopic submucosal dissection (ESD), makes en bloc resection possible for mucosal cancers greater than 2 cm in diameter. 22 The concept and technique of ESD is markedly different from those of conventional EMR. ESD removes tumor lesions using a round cut and submucosal dissection without the use of a snare device. 23 Therefore, the indication criteria for endoscopic resection using ESD were expanded in 2004. For example, ESD is indicated for all intestinal-type mucosal cancers without ulceration regardless of cancer size. The frequency of endoscopic treatment for gastric cancer is expected to increase gradually in the future.
As only a small part of the gastric mucosa is resected, secondary gastric cancer after endoscopic resection of primary gastric cancer often develops at another site in the stomach. The reported frequency of secondary gastric cancer is 3%-7% (Table 4) . We conducted a large-scale, multicenter randomized trial to confirm the effect of H. pylori eradication on secondary and residual gastric cancer after endoscopic resection. 24 This study started in 2003 and is ongoing at present. Eligible subjects are H. pylori-infected patients who have been newly resected by endoscopic treatment for early gastric cancer or who are in the postresection follow-up phase. Patients are being randomly allocated to the eradication or the control arms. Patients will be evaluated by endoscopy at 0.5, 1, 2, and 3 years after randomization. Diagnosis of a new carcinoma at another site of the stomach is defined as the primary end point, and recurrence of tumors at the resection site as a secondary end point. The eradication group and control (noneradication) group are being compared by intention-to-treat, per-protocol, and time-to-recurrence analyses. The significance level is defined as P = 0.01 for interim analyses and P = 0.045 for final analyses. Between April 2001 and July 2003, 544 subjects were enrolled in the study and are being followed up (Table 5 ). An interim analysis was performed in March 2005, when the observed person-years exceeded 750. The P value for the treatment difference at the primary end point did not satisfy the criterion for statistical significance. This study will continue until the observation periods of all currently enrolled subjects exceed 3 years.
Helicobacter pylori infection both initiates and promotes the development of gastric cancer. On this basis, eradication should both inhibit the occurrence of new gastric cancer and reduce the growth rate of those cancers that do occur (Fig. 4) . Because the 3-year follow-up period after successful eradication of this study is too short to evaluate whether eradication prevents a new occurrence of gastric cancer, this study probably evaluated the appearance of clinical cancers developed from occult cancer, that is cancer that existed but was not detectable at the time of endoscopic treatment. If the detection time of residual cancer in the eradication group is delayed compared with that in the control group, then a promoter effect of H. pylori infection can be proved. In other words, H. pylori eradication may decrease the rate of gastric cancer growth.
Conclusion
A retrospective study showed that H. pylori eradication may reduce the incidence of gastric cancer. A random- Fig. 4 . Helicobacter pylori infection both initiates and promotes the development of gastric cancer. On this basis, eradication should both inhibit the occurrence of new gastric cancer and reduce the growth rate of those cancers that do occur ized prospective study is still ongoing. The final analysis is planned for September of this year.
